Mepolizumab in the Management of Severe Eosinophilic Asthma in Adults: Current Evidence and Practical Experience

Overview

Journal Ther Adv Respir Dis

Publisher Sage Publications

Specialties Pharmacology
Pulmonary Medicine

Date 2016 Nov 19

PMID 27856823

Citations 8

Authors

Gilda Varricchi

Diego Bagnasco

Matteo Ferrando

Francesca Puggioni

Giovanni Passalacqua

Giorgio W Canonica

Affiliations

Soon will be listed here.

Abstract

Eosinophils represent approximately 1% of peripheral blood leukocytes in normal donors and their maturation and differentiation in the bone marrow are mainly regulated by interleukin (IL)-5 [Broughton et al. 2015]. IL-5, a cytokine that belongs to the β common-chain family, together with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates also the activation and survival of eosinophils and, to some extent, of basophils. IL-5 binds to a heterodimer receptor composed of the specific subunit IL-5Rα and a common subunit βc shared with IL-3 and GM-CSF. Human eosinophils express approximately a three-fold higher level of IL-5Rα compared with basophils. Major sources of IL-5 are T-helper 2 (Th2) cells, mast cells, CD34+ progenitor cells, invariant natural killer (NK) T-cells, group 2 innate lymphoid cells (ILC2s), and eosinophils themselves. ILC2s control not only eosinophil number but also their circadian cycling through the production of IL-5.

Citing Articles

Biologics and airway remodeling in severe asthma.

Varricchi G, Ferri S, Pepys J, Poto R, Spadaro G, Nappi E Allergy. 2022; 77(12):3538-3552.

PMID: 35950646 PMC: 10087445. DOI: 10.1111/all.15473.

Interleukin-5 in the Pathophysiology of Severe Asthma.

Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica G Front Physiol. 2020; 10:1514.

PMID: 31920718 PMC: 6927944. DOI: 10.3389/fphys.2019.01514.

A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.

Nara M, Saito M, Abe F, Komatsuda A, Wakui H, Takahashi N Intern Med. 2019; 58(24):3583-3587.

PMID: 31391393 PMC: 6949444. DOI: 10.2169/internalmedicine.3406-19.

Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.

Faverio P, Bonaiti G, Bini F, Vaghi A, Pesci A Ther Clin Risk Manag. 2018; 14:2385-2396.

PMID: 30573961 PMC: 6292233. DOI: 10.2147/TCRM.S159949.

Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma.

Bagnasco D, Caminati M, Ferrando M, Aloe T, Testino E, Canonica G Biomed Res Int. 2018; 2018:5698212.

PMID: 30519580 PMC: 6241368. DOI: 10.1155/2018/5698212.

References

Bel E, Wenzel S, Thompson P, Prazma C, Keene O, Yancey S . Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014; 371(13):1189-97. DOI: 10.1056/NEJMoa1403291. View

Hart T, Cook R, Zia-Amirhosseini P, Minthorn E, Sellers T, Maleeff B . Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001; 108(2):250-7. DOI: 10.1067/mai.2001.116576. View

Nussbaum J, Van Dyken S, von Moltke J, Cheng L, Mohapatra A, Molofsky A . Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. 2013; 502(7470):245-8. PMC: 3795960. DOI: 10.1038/nature12526. View

Fallon P, Ballantyne S, Mangan N, Barlow J, Dasvarma A, Hewett D . Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J Exp Med. 2006; 203(4):1105-16. PMC: 2118283. DOI: 10.1084/jem.20051615. View

Wenzel S . Eosinophils in asthma--closing the loop or opening the door?. N Engl J Med. 2009; 360(10):1026-8. DOI: 10.1056/NEJMe0900334. View

Ortega H, Li H, Suruki R, Albers F, Gordon D, Yancey S . Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc. 2014; 11(7):1011-7. DOI: 10.1513/AnnalsATS.201312-454OC. View

Rosas M, Dijkers P, Lindemans C, Lammers J, Koenderman L, Coffer P . IL-5-mediated eosinophil survival requires inhibition of GSK-3 and correlates with beta-catenin relocalization. J Leukoc Biol. 2006; 80(1):186-95. DOI: 10.1189/jlb.1105636. View

Roufosse F, de Lavareille A, Schandene L, Cogan E, Georgelas A, Wagner L . Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol. 2010; 126(4):828-835.e3. PMC: 2950246. DOI: 10.1016/j.jaci.2010.06.049. View

Carretero R, Sektioglu I, Garbi N, Salgado O, Beckhove P, Hammerling G . Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015; 16(6):609-17. DOI: 10.1038/ni.3159. View

10.

Pavord I, Korn S, Howarth P, Bleecker E, Buhl R, Keene O . Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380(9842):651-9. DOI: 10.1016/S0140-6736(12)60988-X. View

11.

Bischoff S, Brunner T, de Weck A, Dahinden C . Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. J Exp Med. 1990; 172(6):1577-82. PMC: 2188769. DOI: 10.1084/jem.172.6.1577. View

12.

Ortega H, Yancey S, Mayer B, Gunsoy N, Keene O, Bleecker E . Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016; 4(7):549-556. DOI: 10.1016/S2213-2600(16)30031-5. View

13.

Kolbeck R, Kozhich A, Koike M, Peng L, Andersson C, Damschroder M . MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010; 125(6):1344-1353.e2. DOI: 10.1016/j.jaci.2010.04.004. View

14.

Broughton S, Nero T, Dhagat U, Kan W, Hercus T, Tvorogov D . The βc receptor family - Structural insights and their functional implications. Cytokine. 2015; 74(2):247-58. DOI: 10.1016/j.cyto.2015.02.005. View

15.

Haldar P, Brightling C, Hargadon B, Gupta S, Monteiro W, Sousa A . Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009; 360(10):973-84. PMC: 3992367. DOI: 10.1056/NEJMoa0808991. View

16.

Haldar P, Brightling C, Singapuri A, Hargadon B, Gupta S, Monteiro W . Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014; 133(3):921-3. DOI: 10.1016/j.jaci.2013.11.026. View

17.

Gleich G, Klion A, Lee J, Weller P . The consequences of not having eosinophils. Allergy. 2013; 68(7):829-35. PMC: 3915877. DOI: 10.1111/all.12169. View

18.

Kim Y, Prussin C, Martin B, Law M, Haverty T, Nutman T . Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol. 2004; 114(6):1449-55. DOI: 10.1016/j.jaci.2004.08.027. View

19.

Spadaro G, Pecoraro A, De Renzo A, Pepa R, Genovese A . Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia. Clin Immunol. 2016; 166-167:103-4. DOI: 10.1016/j.clim.2016.04.001. View

20.

Stein M, Villanueva J, Buckmeier B, Yamada Y, Filipovich A, Assaad A . Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008; 121(6):1473-83, 1483.e1-4. PMC: 2749495. DOI: 10.1016/j.jaci.2008.02.033. View